Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.49 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.46 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.45 |
| ▸ | CCR3 | P51677 | 1/20 | 0.41 |
| ▸ | AMPD2 | Q01433 | 2/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13041443 | 0.87 | OPRL1 (0.58) | C5AR1OPRL1OPRM1OPRK1EGLN1 | |
| SCHEMBL14272799 | 0.82 | C5AR1 (0.48) | PTGDR2C5AR1OPRL1OPRM1OPRK1 | |
| SCHEMBL3737310 | 0.79 | OPRK1 (0.49) | PTGDR2C5AR1PARK7OPRL1OPRM1 | |
| SCHEMBL13041582 | 0.77 | OPRL1 (0.52) | C5AR1OPRL1OPRM1OPRK1EGLN1 | |
| SCHEMBL20783509 | 0.71 | DDR1 (0.58) | PTGDR2OPRL1 | |
| SCHEMBL3141632 | 0.70 | TP53 (0.54) | C5AR1OPRL1OPRM1OPRK1EGLN1 | |
| SCHEMBL18729423 | 0.69 | OPRL1 (0.61) | C5AR1OPRL1OPRM1OPRK1EGLN1 | |
| SCHEMBL13041512 | 0.69 | OPRL1 (0.67) | OPRL1OPRM1OPRK1 | |
| SCHEMBL13041592 | 0.69 | OPRL1 (0.45) | OPRL1OPRM1OPRK1EGLN1 | |
| SCHEMBL5578720 | 0.68 | OPRK1 (0.50) | C5AR1OPRL1OPRM1OPRK1EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280049-A1 | ANTAGONISTS OF PGD2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280049-A1 | ANTAGONISTS OF PGD2 RECEPTORS | PTGDR2, PTGDR, LTB4R2 | PTGDR2 1/4885C5AR1 122/4885PARK7 4036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.